Safety of sunitinib in patients with renal cell carcinoma following nephrectomy.

Expert Opinion on Drug Safety
Luc HeraudetMarine Gross-Goupil

Abstract

The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer. In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting. In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.

References

Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amnon ZismanArie S Belldegrun
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Y Kim, William G Kaelin
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Apr 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L TelliS Srinivas
Apr 4, 2009·Anti-cancer Drugs·Vincent Launay-Vacher, Gilbert Deray
May 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Ravaud
May 21, 2009·Expert Opinion on Investigational Drugs·Hui K GanJennifer J Knox
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Jun 18, 2011·Drugs in R&D·Bernard Escudier, Martin Gore
Mar 21, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Apr 5, 2012·Nature Reviews. Clinical Oncology·Bernard EscudierMartin Gore
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Aug 27, 2013·Seminars in Oncology·Tobias JanowitzTim Eisen
Apr 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierDavid Cella
May 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naomi B HaasRobert S DiPaola
Jul 29, 2015·European Urology·Camillo PortaRobert J Motzer
Jul 29, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BracardaUNKNOWN Rainbow Group
Oct 11, 2016·The New England Journal of Medicine·Alain RavaudUNKNOWN S-TRAC Investigators
Jan 26, 2017·The New England Journal of Medicine·Toni K Choueiri, Robert J Motzer
Sep 14, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerUNKNOWN PROTECT investigators
Dec 24, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fengmin ZhaoNaomi S B Haas
May 31, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G CasaliUNKNOWN ESMO Guidelines Committee and EURACAN
Jun 5, 2018·The New England Journal of Medicine·Arnaud MéjeanBernard Escudier
Nov 10, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M StaehlerA Ravaud
Feb 23, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G CasaliUNKNOWN ESMO Guidelines Committee and EURACAN. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved